BETHESDA, Md--The Breast Cancer Prevention Trial (BCPT), launched
in 1992, will need fewer women than originally estimated for completion.
Although planned for 16,000 women, the trial now has more than
12,000 enrolled, and needs only another 1,000 for completion,
which is expected next year.
The purpose of the trial, being conducted by the NCI-sponsored
National Surgical Adjuvant Breast and Bowel Project (NSABP) is
to determine whether tamoxifen (Nolvadex) can prevent breast cancer
in women at increased risk of the disease.
Because women who have volunteered for the study have had a much
greater underlying risk of breast cancer than anticipated, the
study will be able to get the answers it needs with fewer volunteers.
In addition, the women who have volunteered are so committed that
they are not dropping out at the normal rate.